Page last updated: 2024-08-25

rosiglitazone and vildagliptin

rosiglitazone has been researched along with vildagliptin in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's4 (57.14)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Dowarah, J; Singh, VP1
Baron, MA; Dejager, S; Mills, D; Rosenstock, J; Schweizer, A1
Maldonado-Lutomirsky, M; Niggli, M; Rosenstock, J1
Colette, C; Comenducci, A; Dejager, S; Monnier, L; Vallée, D1
Bundhun, PK; Huang, F; Janoo, G; Teeluck, AR1
Chen, SH; Liu, XN; Peng, Y; Sun, QY1

Reviews

3 review(s) available for rosiglitazone and vildagliptin

ArticleYear
Anti-diabetic drugs recent approaches and advancements.
    Bioorganic & medicinal chemistry, 2020, 03-01, Volume: 28, Issue:5

    Topics: Diabetes Mellitus; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Molecular Structure; Structure-Activity Relationship

2020
Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
    BMC pharmacology & toxicology, 2017, 10-23, Volume: 18, Issue:1

    Topics: Adamantane; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Nitriles; Pioglitazone; Pyrrolidines; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Vildagliptin

2017
Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials.
    Journal of cellular physiology, 2019, Volume: 234, Issue:3

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Exenatide; Female; Glyburide; Humans; Male; Metformin; Network Meta-Analysis; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Sulfonylurea Compounds; Vildagliptin

2019

Trials

2 trial(s) available for rosiglitazone and vildagliptin

ArticleYear
Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
    Diabetes care, 2007, Volume: 30, Issue:2

    Topics: Adamantane; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Edema; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Racial Groups; Rosiglitazone; Thiazolidinediones; Vildagliptin

2007
Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?
    Diabetes technology & therapeutics, 2012, Volume: 14, Issue:10

    Topics: Adamantane; Adult; Aged; Analysis of Variance; Area Under Curve; Basal Metabolism; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrazines; Pyrrolidines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin

2012

Other Studies

2 other study(ies) available for rosiglitazone and vildagliptin

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus.
    Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:6

    Topics: Adamantane; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Nitriles; Pyrrolidines; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Vildagliptin; Weight Gain

2009